Partial
Mostly Aligned
Patient Risk:
High
Summary
The AI-generated claims align with the label on several key safety warnings and the 2 mg tablet strength, but include unsupported/inaccurate statements (injectable form claim, Rx-only status, and several non-opioid/patent-related assertions). Overall, partial alignment with notable omissions and contradictions.
Category Scores
Accurate Statements
Dilaudid (hydromorphone) is an opioid analgesic used for moderate to severe pain management.
Partially supported; Indication states pain severe enough to require an opioid analgesic; nuance about acute vs. non-acute pain noted.
Dilaudid tablets are available in 2 mg strength.
Section 3 lists 2 mg tablets.
As a potent opioid, Dilaudid carries significant risks.
Warnings/Precautions sections 5.2, 5.3, 5.4.
These include the potential for addiction, dependence, and withdrawal symptoms upon cessation.
5.2 (Addiction/Abuse/Misuse) and 5.14 (Withdrawal), plus 9 (Drug Abuse and Dependence).
Respiratory depression is a serious risk of Dilaudid, which can be life-threatening, especially at higher doses or when combined with other CNS depressants.
5.3 and 5.4.
Drowsiness is a common side effect of Dilaudid.
Adverse Reactions (6).
Dizziness is a common side effect of Dilaudid.
Adverse Reactions (6).
Constipation is a common side effect of Dilaudid.
Adverse Reactions (6).
Nausea is a common side effect of Dilaudid.
Adverse Reactions (6).
Itching is a common side effect of Dilaudid.
Adverse Reactions (6).
Unsupported Statements
Dilaudid is a prescription medication.
No explicit Rx-only statement in the provided label sections.
Dilaudid is available in tablet and injectable forms.
Label lists Oral Solution and Tablets; no injectable form shown in provided sections.
AbbVie is the maker of Dilaudid.
Manufacturer information not stated in the provided sections.
Morphine is an opioid analgesic.
Not stated or referenced in the provided label sections.
Oxycodone is an opioid analgesic.
Not stated in the provided label sections.
Fentanyl is an opioid analgesic.
Not stated in the provided label sections.
Acetaminophen is a non-opioid pain reliever.
Not stated in the provided label sections.
NSAIDs are non-opioid pain relievers.
Not stated in the provided label sections.
Non-opioid pain relievers are options for milder pain or as adjuncts.
Not stated in the provided label sections.
Understanding the patent status of a drug is key to anticipating generic competition and potential price reductions.
Patent status and generic market dynamics are not addressed in the label.
Once patent protections expire, generic versions of the drug can enter the market, often leading to lower prices.
Patent status and generics discussion is not in the label.
Contradictions
Low
AI Statement
Dilaudid is available in tablet and injectable forms.
Label Reference
3
Important Omissions
Rx-only status language
Importance:
High
Direct statements about manufacturer
Importance:
Moderate
Explicitly listing other opioids (morphine, oxycodone, fentanyl) as related examples within the label context
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Label identifies addiction/misuse risk, respiratory depression, and CNS depressant interactions with opioids; these risks are substantial and require careful monitoring and risk mitigation.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Injectable form claim and Rx-only language are not supported by the label data; several non-label statements (patent/status) are present.
Suggested Improvement
Correct injectable form assertion; remove non-label statements about prescription status and patent/generic pricing; ensure adverse effects and strength claims are restricted to label-supported items; confirm any additional label sections (e.g., contraindications, interactions) when evaluating completeness.